Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BioWorld Insight on August 16, 2010 titled “If NIH Challenges Genzyme’s Patents, Does Anyone Care?” Wright Bonilla discusses a petition filed with the Department of Health and Human Services urging the National Institutes of Health (NIH) to exercises its march-in rights and grant an open license for the use of patents related to Genzyme Corp.’s Fabry disease drug Fabrazyme. She states that it is unlikely that the NIH would pursue an open license for Genzyme’s product because of the complexity of making biologics like Fabrazyme, adding that the agency has in fact never before exercised its march-in rights.
Related News
May 28, 2025
In the News
Cliff Risman Featured on Hospitality Trends – Transactions at 'almost historic levels'
Foley & Lardner LLP partner Cliff Risman is featured in the Law360 Q&A, "Foley Hospitality Leader Talks Deals In Economic Uncertainty."
May 27, 2025
In the News
Kyle Faget Profiled on Health Care Evolution – 'Only just beginning to see what's possible'
Foley & Lardner LLP partner Kyle Faget is profiled by The Inspirational Leaders for her achievements and vision in health care law.
May 27, 2025
In the News
Foley's Silicon Valley Corporate Additions Featured in Legal Press
Foley & Lardner LLP partners Gurpreet Bal and Shaalu Mehra are highlighted in legal press for their recent arrival to the firm.